全文获取类型
收费全文 | 4105篇 |
免费 | 272篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 102篇 |
妇产科学 | 75篇 |
基础医学 | 519篇 |
口腔科学 | 55篇 |
临床医学 | 351篇 |
内科学 | 1098篇 |
皮肤病学 | 74篇 |
神经病学 | 738篇 |
特种医学 | 80篇 |
外国民族医学 | 1篇 |
外科学 | 352篇 |
综合类 | 6篇 |
预防医学 | 192篇 |
眼科学 | 63篇 |
药学 | 316篇 |
中国医学 | 6篇 |
肿瘤学 | 375篇 |
出版年
2024年 | 12篇 |
2023年 | 64篇 |
2022年 | 131篇 |
2021年 | 206篇 |
2020年 | 130篇 |
2019年 | 150篇 |
2018年 | 169篇 |
2017年 | 102篇 |
2016年 | 143篇 |
2015年 | 181篇 |
2014年 | 175篇 |
2013年 | 237篇 |
2012年 | 357篇 |
2011年 | 367篇 |
2010年 | 205篇 |
2009年 | 184篇 |
2008年 | 278篇 |
2007年 | 221篇 |
2006年 | 207篇 |
2005年 | 150篇 |
2004年 | 156篇 |
2003年 | 159篇 |
2002年 | 122篇 |
2001年 | 47篇 |
2000年 | 37篇 |
1999年 | 29篇 |
1998年 | 18篇 |
1997年 | 8篇 |
1996年 | 14篇 |
1995年 | 12篇 |
1994年 | 7篇 |
1993年 | 9篇 |
1992年 | 11篇 |
1991年 | 13篇 |
1990年 | 13篇 |
1989年 | 12篇 |
1988年 | 6篇 |
1987年 | 5篇 |
1986年 | 9篇 |
1985年 | 8篇 |
1984年 | 7篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1979年 | 7篇 |
1978年 | 4篇 |
1977年 | 9篇 |
1973年 | 3篇 |
1972年 | 2篇 |
1969年 | 2篇 |
排序方式: 共有4418条查询结果,搜索用时 9 毫秒
51.
Luigi Russo Francesco Colangelo Raffaele Cioffi Ilaria Rea Luca De Stefano 《Materials》2011,4(6):1023-1033
Porous silicon samples have been reduced in nanometric particles by a well known industrial mechanical process, the ball grinding in a planetary mill; the process has been extended to crystalline silicon for comparison purposes. The silicon nanoparticles have been studied by X-ray diffraction, infrared spectroscopy, gas porosimetry and transmission electron microscopy. We have estimated crystallites size from about 50 nm for silicon to 12 nm for porous silicon. The specific surface area of the powders analyzed ranges between 100 m2/g to 29 m2/g depending on the milling time, ranging from 1 to 20 h. Electron microscopy confirms the nanometric size of the particles and reveals a porous structure in the powders obtained by porous silicon samples which has been preserved by the fabrication conditions. Chemical functionalization during the milling process by a siloxane compound has also been demonstrated. 相似文献
52.
53.
54.
Angiography vs transesophageal echocardiography‐guided patent foramen ovale closure: A propensity score matched analysis of a two‐center registry
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
55.
56.
Albino Eccher MD Ilaria Girolami MD Ersilia Lucenteforte MD Giancarlo Troncone MD Aldo Scarpa MD Liron Pantanowitz MD 《Cancer cytopathology》2021,129(7):506-516
Malignant mesothelioma is a rare malignancy with a poor prognosis whose development is related to asbestos fiber exposure. An increasing role of genetic predisposition has been recognized recently. Pleural biopsy is the gold standard for diagnosis, in which the identification of pleural invasion by atypical mesothelial cell is a major criterion. Pleural effusion is usually the first sign of disease; therefore, a cytological specimen is often the initial or the only specimen available for diagnosis. Given that reactive mesothelial cells may show marked atypia, the diagnosis of mesothelioma on cytomorphology alone is challenging. Accordingly, cell block preparation is encouraged, as it permits immunohistochemical staining. Traditional markers of mesothelioma such as glucose transporter 1 (GLUT1) and insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) are informative, but difficult to interpret when reactive proliferations aberrantly stain positive. BRCA1-associated protein 1 (BAP1) nuclear staining loss is highly specific for mesothelioma, but sensitivity is low in sarcomatoid tumors. Cyclin-dependent kinase inhibitor 2A (CDKN2A)/p16 homozygous deletion, assessed by fluorescence in situ hybridization, is more specific for mesothelioma with better sensitivity, even in the sarcomatoid variant. The surrogate marker methylthioadenosine phosphorylase (MTAP) has been found to demonstrate excellent diagnostic correlation with p16. The purpose of this review is to provide an essential appraisal of the literature regarding the diagnostic value of many of these emerging biomarkers for malignant mesothelioma in effusion cytology. 相似文献
57.
Licia Iaccarino Tiziana Ottone Valentina Alfonso Laura Cicconi Mariadomenica Divona Serena Lavorgna Serena Travaglini Aleandra Ferrantini Giulia Falconi Constance Baer Monica Usai Fabio Forghieri Adriano Venditti Maria Ilaria Del Principe William Arcese Maria Teresa Voso Torsten Haferlach Francesco Lo-Coco 《American journal of hematology》2019,94(10):1091-1097
Despite the high probability of cure of patients with acute promyelocytic leukemia (APL), mechanisms of relapse are still largely unclear. Mutational profiling at diagnosis and/or relapse may help to identify APL patients needing frequent molecular monitoring and early treatment intervention. Using an NGS approach including a 31 myeloid gene-panel, we tested BM samples of 44 APLs at the time of diagnosis, and of 31 at relapse. Mutations in PML and RARA genes were studied using a customized-NGS-RNA panel. Patients relapsing after ATRA-chemotherapy rarely had additional mutations (P = .009). In patients relapsing after ATRA/ATO, the PML gene was a preferential mutation target. We then evaluated the predictive value of mutations at APL diagnosis. A median of two mutations was detectable in 9/11 patients who later relapsed, vs one mutation in 21/33 patients who remained in CCR (P = .0032). This corresponded to a significantly lower risk of relapse in patients with one or less mutations (HR 0.046; 95% CI 0.011-0.197; P < .0001). NGS-analysis at the time of APL diagnosis may inform treatment decisions, including alternative treatments for cases with an unfavorable mutation profile. 相似文献
58.
V. Isella C. Mapelli N. Morielli D. De Gaspari C. Siri G. Pezzoli A. Antonini M. Poletti U. Bonuccelli L. Picchi A. Napolitano M. Vista A. Greco I. M. Appollonio 《Neurological sciences》2013,34(10):1751-1758
The MiniMental Parkinson (MMP) has been derived from the MiniMental State Examination (MMSE) for the screening of cognitive impairment in Parkinson’s disease by adding subtests that were focused on executive and visuo-spatial impairment more than on memory or language deficits. In this multicenter study, the psychometric and validity properties of the MMP have been evaluated in 69 cognitively intact and 52 cognitively impaired patients with Parkinson’s disease, classified according to their performance at the Dementia Rating Scale. The MMP showed better metrics and convergent validity, and higher screening ability. However, its performance was not fully satisfying in terms of data distribution, coefficient of variation and specificity, and Receiver Operating Characteristic curves did not show clear cut superiority of either scale at their best sensitivity–specificity trade off. The MMP seems to be slightly preferable to the MMSE only at a cut off that favours sensitivity with respect to specificity, for screening purposes. The test is simple and quick, but has limitations in terms of validity. 相似文献
59.
Ilaria Franzese MD Alessandra Francica MD Gabriele Pesarini MD Leonardo Gottin MD Flavio L. Ribichini MD Francesco Onorati MD PhD Giuseppe Faggian MD 《Journal of cardiac surgery》2020,35(8):2093-2096
Balloon rupture is an uncommon complication during balloon-expandable transcatheter aortic valve replacement (TAVR). We describe a balloon rupture and tearing with intraventricular entrapment complicating transapical-TAVR, as well as our bailout retrieval of the failed device. 相似文献
60.
Ilaria Callegari Tobias Derfuss Edoardo Galli 《Presse medicale (Paris, France : 1983)》2021,50(2):104068
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the understanding of possible side effects. Moreover, the evolving knowledge of the disease is paving the way to new and innovative therapeutic approaches, as well as the development of new biomarkers to monitor the therapeutic response and to guide the clinician's therapeutic choices. In this review we provide a comprehensive overview on currently approved therapies in MS and the emerging evidence-based strategies to adopt for initiating, monitoring, and eventually adapting a therapeutic regimen with DMT. 相似文献